BioSpace News Archive

Brings over 20 years of experience in drug development and pharmaceutical manufacturing, as well as Nasdaq listed public company experience

Signature comedy fundraiser helps to fund stomach cancer research.

Phase 2 study will Examine the Effect of Mavrilimumab on the Clinical Profile of Yescarta

Madrigal Pharmaceuticals, Inc. announced the pricing of the previously-announced underwritten secondary offering by investment funds affiliated with Bay City Capital LLC, of 1,200,000 shares of Madrigal’s common stock at the public offering price of $107.85 per share.

The 12th Clinical Trials on Alzheimer’s Disease 2019 was held in San Diego, USA, from December 4-7. At the CTAD, the results of various Alzheimer’s disease clinical trials were shared, and it provided a glimpse into the possibility of treating Alzheimer’s disease.

Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor microenvironment, today announced the appointment of Lara Sullivan, M.D. as Chief Executive Officer and Director.

Glooko®, the global leader in diabetes data management, today announced it has received Privacy Shield certification from the U.S. Department of Commerce

Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced that a hearing date has not yet been scheduled for consideration of the Company’s application materials, filed on November 18, 2019 with the Supreme Court of British Columbia (the “Court”), relating to Court orders sought by the Company in connection with the Company’s voluntary liquidation and dissolution (the “Liquidation”).

HMS (NASDAQ: HMSY) has partnered with Dallas-based CitySquare in its mission of fighting the causes and effects of poverty through service, advocacy and friendship by making a $15,000 donation

Genective, a joint venture between Limagrain and KWS, dedicated to the development of transgenic traits, and AgBiome, a leader in the discovery and development of new technology from microbes, announced today a strategic partnership to accelerate commercialization of coleopteran and lepidopteran resistant transgenic traits with unique modes of action